Marshall Wace’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$224M Sell
3,689,838
-7,154,432
-66% -$417M 0.22% 67
2025
Q4
$585M Buy
10,844,270
+9,310,682
+607% +$448M 0.53% 21
2025
Q3
$69.2M Buy
1,533,588
+1,528,823
+32,084% +$71.4M 0.07% 249
2025
Q2
$221K Buy
+4,765
New +$234K ﹤0.01% 2431
2024
Q4
Sell
-868,109
Closed -$44.9M 2594
2024
Q3
$44.9M Buy
868,109
+612,379
+239% +$28.7M 0.05% 309
2024
Q2
$10.6M Sell
255,730
-618,454
-71% -$27.7M 0.01% 704
2024
Q1
$47.4M Buy
+874,184
New +$44.5M 0.07% 270
2023
Q4
Sell
-339,352
Closed -$19.7M 2197
2023
Q3
$19.7M Sell
339,352
-1,595,177
-82% -$97.7M 0.04% 445
2023
Q2
$124M Buy
+1,934,529
New +$130M 0.24% 79
2023
Q1
Sell
-63,721
Closed -$4.58M 2674
2022
Q4
$4.58M Buy
+63,721
New +$4.8M 0.01% 1240
2022
Q2
Sell
-57,620
Closed -$4.21M 3434
2022
Q1
$4.21M Buy
57,620
+50,100
+666% +$3.36M 0.01% 1497
2021
Q4
$469K Buy
7,520
+1,362
+22% +$79.9K ﹤0.01% 2835
2021
Q3
$365K Sell
6,158
-51,576
-89% -$3.4M ﹤0.01% 2555
2021
Q2
$3.86M Sell
57,734
-688,291
-92% -$44.9M 0.02% 1000
2021
Q1
$47.1M Sell
746,025
-471,700
-39% -$29.3M 0.22% 88
2020
Q4
$75.5M Buy
1,217,725
+847,514
+229% +$52.1M 0.41% 45
2020
Q3
$22.3M Sell
370,211
-75,075
-17% -$4.52M 0.14% 154
2020
Q2
$26.2M Buy
445,286
+433,882
+3,805% +$26M 0.18% 126
2020
Q1
$636K Sell
11,404
-28,177
-71% -$1.72M 0.01% 918
2019
Q4
$2.54M Sell
39,581
-70,306
-64% -$4.03M 0.02% 736
2019
Q3
$5.57M Buy
109,887
+33,361
+44% +$1.57M 0.04% 476
2019
Q2
$3.47M Sell
76,526
-60,463
-44% -$2.82M 0.03% 603
2019
Q1
$6.54M Sell
136,989
-630,878
-82% -$31.4M 0.06% 388
2018
Q4
$39.9M Sell
767,867
-99,754
-11% -$5.36M 0.41% 44
2018
Q3
$53.9M Buy
867,621
+140,539
+19% +$8.34M 0.46% 37
2018
Q2
$40.2M Buy
727,082
+674,457
+1,282% +$36.4M 0.6% 39
2018
Q1
$3.33M Sell
52,625
-250,968
-83% -$16.1M 0.14% 140
2017
Q4
$18.6M Buy
303,593
+215,335
+244% +$13.5M 0.78% 30
2017
Q3
$5.65M Buy
+88,258
New +$5.15M 0.26% 84
2017
Q2
Sell
-30,433
Closed -$1.64M 319
2017
Q1
$1.64M Sell
30,433
-482,749
-94% -$26.5M 0.08% 171
2016
Q4
$30M Sell
513,182
-429,198
-46% -$23.5M 0.2% 138
2016
Q3
$50.8M Buy
942,380
+355,452
+61% +$22.8M 0.36% 67
2016
Q2
$43.2M Sell
586,928
-268,987
-31% -$19M 0.36% 64
2016
Q1
$54.7M Sell
855,915
-1,977,838
-70% -$125M 0.53% 51
2015
Q4
$195M Buy
2,833,753
+1,798,080
+174% +$119M 1.83% 3
2015
Q3
$61.3M Buy
1,035,673
+389,607
+60% +$24.7M 0.75% 25
2015
Q2
$43M Sell
646,066
-189,281
-23% -$12.5M 0.56% 42
2015
Q1
$53.9M Buy
835,347
+804,386
+2,598% +$50.4M 0.7% 20
2014
Q4
$1.83M Sell
30,961
-543,104
-95% -$30.6M 0.02% 473
2014
Q3
$29.4M Buy
+574,065
New +$28.7M 0.42% 55
2014
Q2
Sell
-208,145
Closed -$10.8M 931
2014
Q1
$10.8M Buy
+208,145
New +$11.1M 0.2% 138

Other funds holding BMY

Marshall Wace's BMY Position: Q1 2026 in Review

Marshall Wace reduced its Bristol-Myers Squibb (BMY) stake by 66% in Q1 2026, selling an estimated $417M and leaving 3,689,838 shares worth $224M. The position accounts for 0.22% of the portfolio, ranked #67.

Marshall Wace first reported a position in BMY in Q1 2014 and has held it in 41 quarters since. The position peaked at $585M in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Marshall Wace held 3,689,838 shares of Bristol-Myers Squibb worth $224M as of Q1 2026.
  • Marshall Wace sold 7,154,432 Bristol-Myers Squibb shares in Q1 2026, an estimated $417M.
  • Bristol-Myers Squibb made up 0.22% of Marshall Wace's portfolio in Q1 2026, its #67 holding.
  • Marshall Wace first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 41 quarters since.
  • Marshall Wace's Bristol-Myers Squibb position peaked at $585M in Q4 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.